Based on 5 analysts giving stock ratings to TScan Therapeutics Inc in the past month.
In the current month, TCRX has received 2 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. TCRX average Analyst price target in the last month is 2.667.
Based on analysts' estimates, TCRX EPS is projected to reach -0.163 in FY2026Q4, following reported EPS of -0.254 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.25, while TScan Therapeutics IncTCRX's earnings per share (EPS) for the previous quarter was USD -0.23. EPS for the next quarter is expected at USD -0.16.